Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 42 min 59 sec ago

Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium

Mon, 01/25/2016 - 15:26
CAMBRIDGE, Mass., Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, announced that three poster presentations were hig...
Biopharmaceuticals, Oncology, Gastroenterology
Boston Biomedical, Napabucasin, cancer stem cell, STAT3

Piramal Critical Care and Cumberland Pharmaceuticals Announce Launch of Caldolor and Vaprisol Co-Promotion

Mon, 01/25/2016 - 15:21
Piramal Critical Care begins promoting Cumberland's Caldolor® and Vaprisol® brands BETHLEHEM, Pa. and NASHVILLE, Tenn., Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Piramal Critical Care, an integral business unit of Piramal Enter...
Biopharmaceuticals, Distribution, Product Launch
Cumberland Pharmaceuticals, Piramal Critical Care, Caldolor, ibuprofen, Vaprisol

Millennium Healthcare Inc. Announces New Healthcare Product Launch

Mon, 01/25/2016 - 15:16
MELVILLE, NEW YORK--(Healthcare Sales & Marketing Network) - Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced the Company has added a new offering, UroVal, to its growing product and s...
Devices, Urology, Product Launch
Millennium Healthcare, UroVal

Steba Biotech Completes its European Phase 3 Clinical Trial of TOOKAD(R) in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency

Mon, 01/25/2016 - 13:26
LUXEMBOURG, Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Steba Biotech, a privately owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announ...
Biopharmaceuticals, Oncology, Regulatory
Steba Biotech, TOOKAD, padeliporfin, photodynamic

Vertice Pharma appoints Dr. Indranil Nandi as Vice President, Research and Development

Mon, 01/25/2016 - 13:19
BERKELEY HEIGHTS, N.J., Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Vertice Pharma today announced that it has appointed Dr. Indranil Nandi as Vice President, Research & Development effective today. "We are delighted to welcome Dr. ...
Biopharmaceuticals, Personnel
Vertice Pharma

BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment

Mon, 01/25/2016 - 13:13
BL-7010 receives designation as Class IIb medical device TEL AVIV, Israel, January 25, 2016 -- (Healthcare Sales & Marketing Network) -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensi...
Biopharmaceuticals, Devices, Regulatory
BioLineRx, Celiac disease, BL-7010

Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer

Sat, 01/23/2016 - 04:00
BEVERLY, MA--(Healthcare Sales & Marketing Network) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applicati...
Biopharmaceuticals, Oncology, FDA
Cellceutix, Kevetrin, Brilacidin-OM, Pancreatic Cancer

BONESUPPORT(TM) Announces Appointment Of Life Sciences Industry Veteran, Richard Davies, As New Chief Executive Officer

Fri, 01/22/2016 - 19:09
Mr. Davies Brings over 25 Years of Life Sciences Industry Experience to BONESUPPORT™ Current Chief Executive Officer, Lloyd Diamond , to Transition to Role of Chief Business Officer LUND, Sweden , Jan. 22, 2016 -- (Healthcare Sales & Marketing Networ...
Devices, Orthopaedic, Personnel
BONESUPPORT, CERAMENT, injectable bone

U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

Fri, 01/22/2016 - 18:43
BOTOX® is the First and Only FDA-Approved Neurotoxin Treatment for Both Upper and Lower Limb Spasticity DUBLIN, Jan. 22, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company today announced t...
Biopharmaceuticals, FDA
Allergan, BOTOX, botulinum toxin, spasticity

InspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board

Fri, 01/22/2016 - 13:48
Enhances Commercial and Development Execution, Reduces Operating Cost Structure, Strengthens Board of Directors BOSTON, MA--(Healthcare Sales & Marketing Network) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a l...
Devices, Interventional, Personnel
InspireMD, CGuard, Embolic Prevention System, MGuard, MicroNe

Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma(R) Gene Expression Classifier

Fri, 01/22/2016 - 13:40
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 -- (Healthcare Sales & Marketing Network) -- Veracyte, Inc. (VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data demonstrating the ability of the Afirma Gene Exp...
Diagnostics, Oncology
Veracyte, Afirma Gene Expression Classifier, molecular cytology

IntelGenx Strengthens Senior Management Team

Fri, 01/22/2016 - 13:35
SAINT-LAURENT, QUEBEC--(Healthcare Sales & Marketing Network) - IntelGenx Corp. (TSX VENTURE:IGX)(IGXT), today announced that it has strengthened its management team with the appointment of Mr. Robert Bechard to the position of Vice President, Corporate De...
Biopharmaceuticals, Drug Delivery, Personnel
IntelGenx, FORFIVO XL

Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Fri, 01/22/2016 - 13:28
Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol First Approval for Amgen and Astellas Joint Venture THOUSAND OAKS, Calif., Jan. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced th...
Biopharmaceuticals, Regulatory
Amgen, Repatha, evolocumab, hypercholesterolemia

Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology

Thu, 01/21/2016 - 17:05
SAN DIEGO, Jan. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Halozyme Therapeutics, Inc. (HALO) today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's p...
Biopharmaceuticals, Drug Delivery, Licensing
Halozyme, ENHANZE, hyaluronidase, subcutaneous

Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)

Thu, 01/21/2016 - 13:28
Single-Dose Option Approved for Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) DUBLIN, Jan. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today announ...
Biopharmaceuticals, FDA
Allergan, DALVANCE, dalbavancin, ABSSSI

VIBERZI(TM) (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine

Thu, 01/21/2016 - 13:20
VIBERZI has been approved for use in the United States in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D) VIBERZI demonstrated effective and sustained relief of abdominal pain and diarrhea IBS-D can be debilitating, affecti...
Biopharmaceuticals, Gastroenterology
Allergan, VIBERZI, irritable bowel syndrome, IBS-D

AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery

Thu, 01/21/2016 - 13:10
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif., Jan. 21, 2016 -- (Healthcare Sales & Marketing Network) -- AcelRx Pharmaceuticals, Inc. (ACRX) today announc...
Biopharmaceuticals, Drug Delivery
AcelRx Pharmaceuticals, sublingual, sufentanil, SAP301, Zalviso

vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury

Thu, 01/21/2016 - 12:55
Phase III registration study of VAS203 to commence in H1 2016 WÜRZBURG, Germany, January 21, 2016 -- (Healthcare Sales & Marketing Network) -- vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatm...
Biopharmaceuticals, Neurology, Venture Capital
vasopharm GmbH, Traumatic Brain Injury, VAS203

SI-BONE, Inc. Announces European Expansion with Formation of SI-BONE UK Ltd and Key Additions to Management Team

Wed, 01/20/2016 - 19:53
Appoints Richard Moss, General Manager, UK & Ireland and Silvio Tarantino, Finance Director, EMEA SAN JOSE, Calif., Jan. 20, 2016 -- (Healthcare Sales & Marketing Network) -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse I...
Devices, Orthopaedic, Neurosurgery, Personnel
SI-BONE, iFuse Implant System, sacroiliac

Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection(R) as a Treatment of Middle East Respiratory Syndrome (MERS)

Wed, 01/20/2016 - 19:50
PHILADELPHIA, Jan. 20, 2016 -- (Healthcare Sales & Marketing Network) -- Hemispherx Biopharma, Inc. (HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has forwarded to Hemispherx both its Public Summ...
Biopharmaceuticals, Regulatory
Hemispherx Biopharma, Alferon N Injection, interferon alfa-n3

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong